BUZZ-Verrica Pharma climbs after EU nod clears path for skin drug filing
Reuters
Oct 21
BUZZ-Verrica Pharma climbs after EU nod clears path for skin drug filing
** Shares of drug developer Verrica Pharmaceuticals VRCA.O rise 17% to $5.17 in extended trading
** Co says it received positive feedback from the European Medicines Agency for its skin disease treatment, Ycanth
** Co plans to submit a regulatory filing for the drug in the European Union as early as the fourth quarter of 2026
** The drug, already approved in the U.S. and Japan to treat molluscum contagiosum, a common viral skin infection that spreads through direct contact and mostly affects children
** Stock down 36% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.